424 completed, 138 recruiting, 118 terminated, 114 unknown. 439 Phase 2, 219 Phase 1, 97 Not applicable, 82 Phase 3, 16 Phase 4.
Follow Metastatic Breast Cancer: new trials by email Literature Review of Metastatic Breast Cancer trials Research Report on Metastatic Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients Core Intervention, EHR Integration (On v. Off), Weekly Coaching - Metastatic Breast Cancer, Metastatic Breast Cancer (MBC) | Not applicable | Not yet recruiting | Northwestern University | 224 | 2027-01-01 | 2026-10-01 |
| A Study to Learn More About Tukysa Once it is Out in the Korean Market HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer | Not yet recruiting | Pfizer | 600 | 2027-01-01 | 2025-11-17 | |
| Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment - Breast Cancer, Metastatic, Metastatic Breast Cancer | Not applicable | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 74 | 2026-11-01 | 2026-09-18 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) Taletrectinib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Suspended | Megan Kruse, MD | 61 | 2026-10-01 | 2026-06-05 |
| CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer Cryoablation, Patient-Reported Outcome Assessment - Metastatic Breast Cancer | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 42 | 2026-10-01 | 2026-06-30 |
| Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer Alisertib - HR+/HER2+ Breast Cancer, Metastatic Breast Cancer | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 10 | 2026-10-01 | 2026-09-29 |
| A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer SSGJ-612 (HER2-targeted antibody), HER2-targeted ADC - Metastatic Breast Cancer | Phase 2 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 87 | 2026-09-21 | 2026-10-14 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer Demographics/Lifestyle Survey - Metastatic Breast Cancer | Not applicable | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-08-21 | 2026-09-25 |
| SMP-656 for HER2-Positive Advanced Breast Cancer SMP-656 Injection - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Chengdu SciMount Pharmatech Co., Ltd. | 60 | 2026-08-10 | 2026-10-15 |
| Evaluation of a Patient-Centered Decision-Making Support Tool for Older Adults With Advanced Breast Cancer and Their Care Partners Decision-making support tool - Metastatic Breast Cancer | Not applicable | Not yet recruiting | University of Rochester | 150 | 2026-08-01 | 2026-05-26 |
| Generative AI Patient Education Module for Breast Oncology Survey (Participant), OpenEvidence CareConnect, Survey (Provider) - Breast Cancer, Metastatic Breast Cancer | Not applicable | Recruiting | University of California, San Francisco | 35 | 2026-07-14 | 2026-08-06 |
| Pulsed Electric Field Ablation for Metastatic Breast Cancer Pulsed Electric Field (PEF) System, Questionnaires, Tumor Ablation - Metastatic Breast Cancer, Breast Cancer | Not applicable | Recruiting | University of California, San Francisco | 20 | 2026-06-29 | 2026-09-18 |
| HER2-positive Metastatic Breast Cancer in Kazakhstan Metastatic Breast Cancer | Recruiting | AstraZeneca | 240 | 2026-06-12 | 2026-10-08 | |
| Shared Decision Making for Patients With HER2-negative Metastatic Breast Cancer (SDM-01) Shared Decision Making (SDM) Support Program - Breast Cancer, HER2 Negative Breast Cancer | Not applicable | Not yet recruiting | Federico II University | 120 | 2026-06-01 | 2026-05-11 |
| First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126 - Metastatic Breast Cancer, Metastatic Prostate Cancer | Early Phase 1 | Recruiting | Integrated Haematology and Oncology Network | 20 | 2026-05-28 | 2026-06-10 |
| Fast-Her: Fasting Effects on Breast Cancer Treatment Normal Eating, Prolonged Fasting - Metastatic Breast Cancer | Not applicable | Recruiting | University of Minnesota | 15 | 2026-05-18 | 2026-07-13 |
| A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors Oral Paclitaxel in combination with Encequidar tablet - Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Health Hope Pharma | 46 | 2026-05-01 | 2026-05-12 |
| A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. p95HER2.CAR-TECH2Me - Metastatic Gastric Cancer, Metastatic Breast Cancer | Phase 1 | Recruiting | Vall d'Hebron Institute of Oncology | 15 | 2026-04-29 | 2026-05-22 |
Showing 20 of 912. Sign in to see all of them.
Breast Neoplasms (912) · Neoplasm Metastasis (74) · Triple Negative Breast Neoplasms (55) · Neoplasms (25) · Prostatic Neoplasms (19) · Colorectal Neoplasms (18) · Lung Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (16) · Brain Neoplasms (13) · Stomach Neoplasms (13) · Ovarian Neoplasms (12) · Motor Activity (9) · Colonic Neoplasms (8) · Melanoma (8) · Carcinoma, Renal Cell (7)
Neoplasms by Site (912) · Skin Diseases (912) · Skin and Connective Tissue Diseases (912) · Breast Diseases (910) · Neoplasms (887) · Pathological Conditions, Signs and Symptoms (99) · Pathologic Processes (88) · Neoplastic Processes (79) · Digestive System Diseases (38) · Digestive System Neoplasms (36) · Gastrointestinal Diseases (35) · Urogenital Diseases (34) · Urogenital Neoplasms (34) · Gastrointestinal Neoplasms (33) · Lung Diseases (33)
Fulvestrant (84) · Capecitabine (82) · Trastuzumab (73) · Paclitaxel (65) · palbociclib (51) · Letrozole (43) · Vinorelbine (39) · eribulin (35) · Docetaxel (34) · Bevacizumab (32) · exemestane (31) · Gemcitabine (30) · Lapatinib (30) · abemaciclib (29) · Everolimus (27)
Fudan University (25) · Novartis Pharmaceuticals (20) · Memorial Sloan Kettering Cancer Center (19) · Eli Lilly and Company (18) · AstraZeneca (16) · Pfizer (15) · Dana-Farber Cancer Institute (13) · Genentech, Inc. (12) · Consorzio Oncotech (11) · Hoffmann-La Roche (11) · UNC Lineberger Comprehensive Cancer Center (10) · UNICANCER (10) · MedSIR (9) · SCRI Development Innovations, LLC (9) · R-Pharm (8)
United States (410) · France (111) · Spain (105) · China (100) · Italy (89) · Germany (71) · United Kingdom (67) · Belgium (63) · South Korea (63) · Canada (56) · Australia (44) · Taiwan (40) · Netherlands (34) · Brazil (31) · Poland (28)
Xichun Hu, MD, PhD (5) · Gary N Schwartz, MD (4) · Kathy Miller, MD (4) · Anne Schott, MD (3) · Denise A. Yardley, M.D. (3) · Joyce O'Shaughnessy, MD (3) · Kathryn H Schmitz, PhD (3)
PMID 34037241, PMID 39024777, PMID 20299316, PMID 20430905, PMID 25473312, PMID 29522361, PMID 30837503, PMID 33084020, PMID 36882736, PMID 37972723, PMID 10561360, PMID 10737767, PMID 12010786, PMID 12411295, PMID 12610500, PMID 12759326, PMID 12816983, PMID 14615453, PMID 14998846, PMID 15215160, PMID 15218292, PMID 15313917, PMID 15365776, PMID 15503313, PMID 15569976, PMID 15629410, PMID 15681523, PMID 15755984, PMID 15841203, PMID 15905493, PMID 16172161, PMID 16172168, PMID 16236737, PMID 16557261, PMID 16699374, PMID 16897431, PMID 17016557, PMID 17135638, PMID 17320482, PMID 17374151, PMID 17647245, PMID 18054441, PMID 18443902, PMID 18551042, PMID 18565579, PMID 18573906, PMID 18757267, PMID 18834631, PMID 18854571, PMID 19097774
2023 (13), 2014 (9), 2015 (7), 2019 (7), 2009 (5), 2016 (5), 2018 (5), 2008 (4), 2017 (4), 2004 (2), U01CA168426 (2), 2005 (1), K07CA218167 (1), K08CA252639 (1), K08CA267189 (1)